Fisher Scientific Company L.L.C.

Fisher Scientific Company L.L.C., operating through its Fisher Healthcare division, supplies laboratory reagents, diagnostic consumables, microbiology media, and medical equipment to the federal healthcare enterprise as a large for-profit prime contractor competing exclusively in full-and-open, unrestricted competition across 13,583 recent federal awards worth $1.06 billion in combined potential value. A subsidiary of Thermo Electron Corporation and registered federal contractor since 2002, Fisher Healthcare operates from Pittsburgh, Pennsylvania, and Houston, Texas locations, anchoring its federal footprint on the GSA Federal Supply Schedule 65-VII (In Vitro Diagnostics, Reagents, Test Kits) and single-award indefinite-delivery contracts and blanket purchase agreements across the Veterans Health Administration, Indian Health Service, Defense Health Agency, and Department of Health and Human Services.

The vendor's capability portfolio centers on laboratory consumables and diagnostic materials. Representative recent prime work includes a $2.75 million indefinite-delivery contract with VA Veterans Integrated Service Network 17 (September 2026) for core and toxicology supplies; a $6.0 million Defense Health Agency blanket purchase agreement (May 2025) for microbiology media, specimen collection supplies, and related medical supplies; a $655.7 million indefinite-delivery contract with VISN 16 (May 2025) for Human Papillomavirus testing services; a $1.084 million order from VISN 22 (February 2026) for oncology reagents and molecular testing consumables including Oncomine Precision Assay kits and Ion Torrent reagents; and a $3.196 million order from VISN 16 (July 2025) for DNA and RNA molecular testing reagents and consumables. Smaller single-order work spans laboratory equipment (freezers, centrifuges, imaging systems, tissue processors, biosafety cabinets), specialty diagnostics (allergy and autoimmune testing reagents, serology test kits, HPV testing, microbiology identification tests), and surveillance supplies (BioWatch program inventory).

Customer concentration is moderate and geographically dispersed across 132 federal agencies. The top five funding agencies—Indian Health Service (998 awards, $29 million), VISN 17 (280 awards, $21.3 million), Navy Bureau of Medicine and Surgery (257 awards, $15.4 million), HHS Office of the Assistant Secretary for Administration (219 awards, $12 million), and Army Medical Command (156 awards, $11.9 million)—account for approximately 14 percent of award count coverage and 10 percent of potential-value coverage. The Indian Health Service leads both rankings, reflecting heavy volume and dollar commitment; VISN 19 ranks second by potential value ($26.8 million across 93 awards), signaling concentration of larger-dollar vehicles and orders within specific VA networks.

Vehicle position reflects heavy reliance on GSA Schedule 65-VII. The Invitro Diagnostics, Reagents, Test vehicle anchors 6,038 task orders worth $142.8 million in combined potential value. Fisher Healthcare holds multiple single-award blanket purchase agreements and indefinite-delivery contracts with individual VISNs, including the $460.3 million VISN 4 BPA for microbiology media and supplies (October 2023–September 2027); the $1.0 million VISN 22 microbiology media BPA (March 2025–March 2030); the $3.8 million VISN 19 Fisher GenExus reagents and maintenance BPA (May 2023–May 2028); and the $3.1 million VISN 17 Thermo Fisher supplies indefinite-delivery contract. These vehicles and recurring task orders demonstrate established customer relationships and procurement infrastructure rather than broad multi-agency government-wide vehicles. Secondary vehicles include Federal Supply Schedule V797P4425A (158 task orders, $2 million) and several HHS Indian Health Service indefinite-delivery and BPA contracts.

Activity has declined in recent years—80 awards in 2022 declining to 36 in 2026—with 35 awards (combined potential value $5.6 million) reaching ultimate completion within the next twenty-four months, creating modest recompete exposure. The vendor competes across five primary NAICS codes: In-Vitro Diagnostic Substance Manufacturing (5,868 awards), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (356 awards), Surgical Appliance and Supplies Manufacturing (275 awards), Analytical Laboratory Instrument Manufacturing (193 awards), and Other Professional Equipment and Supplies Merchant Wholesalers (139 awards). Work is performed nationwide and overseas, with administrative oversight and primary warehousing at Pittsburgh and Houston locations. The vendor operates with no subcontractor footprint in the source material—all 13,583 awards are prime contracts—and holds no set-aside certifications, positioning Fisher Healthcare as a large unrestricted competitor dependent on technical capability and pricing in full-and-open federal procurements serving the healthcare and life-sciences sectors.